Human Molecular Genetics Advance Access originally published online on February 24, 2006
Human Molecular Genetics 2006 15(7):1049-1058; doi:10.1093/hmg/ddl020
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Familial hypomagnesemia with hypercalciuria and nephrocalcinosis: blocking endocytosis restores surface expression of a novel Claudin-16 mutant that lacks the entire C-terminal cytosolic tail


1Department of Pediatric Nephrology and Center for Cardiovascular Research, Charité, Berlin, Germany, 2Epithelial Cell Biology Laboratory, Institute of Molecular and Cell Biology, Singapore and 3Max-Delbrück-Center of Molecular Medicine, Berlin, Germany
* To whom correspondence should be addressed at: Institute of Molecular and Cell Biology, 61 Biopolis Drive, Singapore 138673, Singapore, Email: hunziker{at}imcb.a-star.edu.sg
Received November 8, 2005; Revised January 6, 2006; Accepted February 3, 2006
Mutations in the gene for Claudin-16 (CLDN16) are linked to familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC), a renal Mg2+ and Ca2+ wasting disorder that leads to progressive kidney failure. More than 20 mutations have been identified in CLDN16, which, with a single exception, affect one of two extracellular loops or one of four transmembrane domains of the encoded protein. Here, we describe a novel missense mutation, Cldn16 L203X, which deletes the entire C-terminal cytosolic domain of the protein. Surface expression of Cldn16 L203X is strongly reduced and the protein is instead found in the endoplasmic reticulum (ER) and lysosomes. ER-retained Cldn16 L203X is subject to proteasomal degradation. Cldn16 L203X present in lysosomes reaches this compartment following transport to the plasma membrane and endocytosis. Blocking clathrin-mediated endocytosis increases surface expression of Cldn16 L203X. Thus, endocytosis inhibitors may provide a novel therapeutic approach for FHHNC patients carrying particular Cldn16 mutations.
The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
L. Cukierman, L. Meertens, C. Bertaux, F. Kajumo, and T. Dragic Residues in a Highly Conserved Claudin-1 Motif Are Required for Hepatitis C Virus Entry and Mediate the Formation of Cell-Cell Contacts J. Virol., June 1, 2009; 83(11): 5477 - 5484. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Lanaspa, A. Andres-Hernando, C. J. Rivard, Y. Dai, and T. Berl Hypertonic stress increases claudin-4 expression and tight junction integrity in association with MUPP1 in IMCD3 cells PNAS, October 14, 2008; 105(41): 15797 - 15802. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Angelow, R. Ahlstrom, and A. S. L. Yu Biology of claudins Am J Physiol Renal Physiol, October 1, 2008; 295(4): F867 - F876. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Konrad, J. Hou, S. Weber, J. Dotsch, J. A. Kari, T. Seeman, E. Kuwertz-Broking, A. Peco-Antic, V. Tasic, K. Dittrich, et al. CLDN16 Genotype Predicts Renal Decline in Familial Hypomagnesemia with Hypercalciuria and Nephrocalcinosis J. Am. Soc. Nephrol., January 1, 2008; 19(1): 171 - 181. [Full Text] [PDF] |
||||
![]() |
D. Muller, P. J. Kausalya, D. Bockenhauer, J. Thumfart, I. C. Meij, M. J. Dillon, W. v. Hoff, and W. Hunziker Unusual Clinical Presentation and Possible Rescue of a Novel Claudin-16 Mutation J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 3076 - 3079. [Abstract] [Full Text] [PDF] |
||||




